This information is valid for the Slovak Republic and may differ for other countries. For detailed information, please contact the relevant foreign representative:

http://www.imuna.sk/en/o-nas/zahranicne-zastupenia-a-business-development/

Abridged Drug Information

Name of drug: CARBOCIT tablets. Composition: One tablet contains carbo activatus 320 mg, bismuthi subgallas 25 mg and acidum citricum monohydricum 3 mg. Pharmaceutical form Tablet. Therapeutic indications: Acute diarrhoea caused by food poisoning, mild viral and bacterial intestinal infections, diarrhoea associated with a variety of underlying conditions (diabetes mellitus), flatulence, indigestion, irritable bowel syndrome, ulcerative colitis, gastritis, and gastroenteritis. The drug is intended for treatment of adults, adolescents and children over 3 years of age. Dosage and method of administration**:** Adults and adolescents*:* The usual dose is 2-4 tablets 3-4 times daily, in diarrhoea 4-5 tablets 3-4 times daily. Administration to children from 3 years of age: The usual dose is 2-4 tablets 3-4 times daily. Tablets should be swallowed whole with a small amount of water or allowed to disintegrate in a small amount of water Administration to children: always in the form of a suspension; one dose should be swallowed with a glass of water or warm tea. Contraindications: The drug is not intended for treatment of children below 3 years of age. CARBOCIT must not be used in known or suspected hypersensitivity to bismuth compounds. Special precautions: CARBOCIT may cause blackening of stools that may mask gastrointestinal bleeding. The drugs may decrease the absorption and thus the effect of other drugs administered orally, and therefore an interval of at least two hours should be maintained between the administration of CARBOCIT and other drugs. Women using oral contraceptives should be secured by another method of contraception while taking CARBOCIT. CARBOCIT is not sufficient in treatment of infectious diarrhoea. Patients with rare hereditary fructose intolerance, glucose-galactose malabsorption or sucrose-isomaltase deficiency must not use this drug. Drug and other interactions: Concurrent administration of CARBOTOX and oral medicinal products is not appropriate as their absorption could be clearly limited. Use in pregnancy and lactation: Administration of CARBOCIT is not recommended during pregnancy and lactation. Effects on ability to drive or use machines: None. Adverse events: slowed absorption rate of concomitantly administered oral drugs, blackening of stools. Packaging: 20 tablets. Marketing authorisation holder: IMUNA PHARM, a.s., Jarková 17, 082 22 Šarišské Michaľany, Slovenská republika. Method of dispensing: The drug is not subject to medical prescription. Detailed information is provided in the Summary of Product Characteristics of CARBOTOX. Date of the last revision of the text: May 2014